Suvorexant

Suvorexant
Systematic (IUPAC) name
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 1030377-33-3 N
ATC code  ?
PubChem CID 24965990
Chemical data
Formula C23H23ClN6O2 
Mol. mass 450.920 g/mol (free base)
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Suvorexant (MK-4305) is an orexin receptor antagonist in development by Merck & Co.[1][2][3] This drug for sleep disorders has passed Phase II trials, and is one of several such compounds currently in development, the others being Actelion's ACT-078573 and GlaxoSmithKline's SB-649,868.

References

  1. ^ Christopher D. Cox, Michael J. Breslin, David B. Whitman, John D. Schreier, Georgia B. McGaughey, Michael J. Bogusky, Anthony J. Roecker, Swati P. Mercer, Rodney A. Bednar, Wei Lemaire, Joseph G. Bruno, Duane R. Reiss, C. Meacham Harrell, Kathy L. Murphy, Susan L. Garson, Scott M. Doran, Thomayant Prueksaritanont, Wayne B. Anderson, Cuyue Tang, Shane Roller, Tamara D. Cabalu, Donghui Cui, George D. Hartman, Steven D. Young, Ken S. Koblan, Christopher J. Winrow, John J. Renger and Paul J. Coleman. (2010). "Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia.". Journal of Medicinal Chemistry 53 (14): 5320-5332. doi:10.1021.2Fjm100541c.  edit
  2. ^ Carl A. Baxter, Ed Cleator, Karel M. J. Brands, John S. Edwards, Robert A. Reamer, Faye J. Sheen, Gavin W. Stewart, Neil A. Strotman, and Debra J. Wallace. (2011). "The First Large-Scale Synthesis of MK-4305: A Dual Orexin Receptor Antagonist for the Treatment of Sleep Disorder.". Organic Process Research and Development 15 (2): 367-375.  edit
  3. ^ Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, Scott M. Doran, Pamela L. Tannenbaum, Michael J. Breslin, Susan L. Garson, Steven V. Fox, Charles M. Harrell, Joanne Stevens, Duane R. Reiss, Donghui Cui, Paul J. Coleman and John J. Renger. (2011). "Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist.". Journal of Neurogenetics 25 (1-2): 52-61.  edit